Alnylam Pharmaceuticals
ALNY
#571
Rank
NZ$62.92 B
Marketcap
$487.84
Share price
-1.36%
Change (1 day)
64.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.3 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.09 Billion. In 2023 the company made an earning of -NZ$0.56 Billion, an increase over its 2022 earnings that were of -NZ$1.73 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$0.3 Billion-46.43%
2023 -NZ$0.56 Billion-67.84%
2022 -NZ$1.73 Billion36.93%
2021 -NZ$1.26 Billion-8.04%
2020 -NZ$1.37 Billion-15.66%
2019 -NZ$1.62 Billion12.23%
2018 -NZ$1.45 Billion62.91%
2017 -NZ$0.89 Billion17.78%
2016 -NZ$0.76 Billion43.44%
2015 -NZ$0.53 Billion60.69%
2014 -NZ$0.33 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$97.12 Million27.48%
2010 -NZ$76.18 Million-10.92%
2009 -NZ$85.52 Million95.77%
2008 -NZ$43.69 Million
2006 -NZ$69.98 Million-9.13%
2005 -NZ$77.02 Million34.74%
2004 -NZ$57.16 Million36.79%
2003 -NZ$41.79 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$1.03 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.80 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.22 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.21 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$73.29 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$22.55 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$13.12 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$0.74 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel